Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.94 USD | +3.97% | -7.94% | -24.79% |
05-10 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
05-09 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.79% | 2.74B | |
+5.27% | 111B | |
+12.15% | 105B | |
-12.91% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-11.18% | 16.96B | |
+4.91% | 13.7B | |
+36.52% | 12.45B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating